Safety and immunogenicity of Ad26.COV2.S in adolescents: Phase 2 randomized clinical trial

Jelena Tica(Janssen (Switzerland)), Anne Marit de Groot, Veronica V. Rezelj(Human Vaccines Project Europe), Julio César Orellana, Macaya Douoguih(Johnson & Johnson (Netherlands)), Parshottam Koradia, Frank Struyf(Janssen (Belgium)), Pravin Dinkar Supe, Deepti Thandaveshwara, Javier Ruiz‐Guiñazú(University of Maryland, Baltimore), Ana Estela Gamiño-Arroyo, Marisa Márcia Mussi‐Pinhata(Universidade de São Paulo), Vitalija van Paassen(Janssen (Switzerland)), Lee Fairlie(University of the Witwatersrand), Jorge Pinto(Universidade Federal de Minas Gerais), Gustavo Akerman Augusto, Benoît Baron(Astellas Pharma (Netherlands)), Mathieu Le Gars(University of Maryland, Baltimore), Abiel Mascareñas, Nadine C. Salisch(Human Vaccines Project Europe), Javier Zaidman(Centro Médico ABC), Gert C. Scheper(University of Maryland, Baltimore)

Human Vaccines & Immunotherapeutics

January 27, 2025

10.1080/21645515.2025.2450120

Cited by 3

Related Papers

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

|The Lancet|2020|5k

A SARS-CoV-2 protein interaction map reveals targets for drug repurposing

|Nature|2020|4.9k

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

|New England Journal of Medicine|2021|2.6k

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

|The Lancet|2021|1.2k

The Global Phosphorylation Landscape of SARS-CoV-2 Infection

|Cell|2020|1.2k